The Life Sciences team advised Blueprint Medicines on its strategic collaboration with Proteovant Therapeutics that will leverage Proteovant Therapeutics’ artificial intelligence-enhanced targeted protein degradation platform and Blueprint Medicine’s small molecule precision medicine capabilities to address medical needs in oncology and hematology.
Under the terms of the agreement, Proteovant will receive a $20 million upfront payment and will be eligible to receive up to an additional $632 million in potential research, development, regulatory and commercialization milestone payments plus tiered royalties from mid- to high-single digits on net sales on the first two program targets, subject to adjustment in specified circumstances.
Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders.
Proteovant Therapeutics is leveraging the process of protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases.
The Goodwin team was led by Noelle Dubiansky and Nancy L. Urizar, with invaluable assistance from Dan Karelitz (Tax), Theresa Kavanaugh (IP), and Paul Jin (Antitrust).
For more details, read the press release and article in Endpoints.